UNITED STATES SECURITIES AND EXCHANGE COMMISSION December 21, 2017

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933 AND THE SECURITIES EXCHANGE ACT OF 1934

FibroGen, Inc. File Nos. 1-36740 and 333-199069

CF#35567

FibroGen, Inc. submitted an application under Rules 406 and 24b-2 requesting an extension of previous grants of confidential treatment for information it excluded from the Exhibits to a Form S-1 filed on October 1, 2014, as amended, and for information it excluded from Exhibit 10.18 to the Form S-1 filed on October 1, 2014, as modified by the same contract refiled with fewer redactions as Exhibit 10.16 to a Form 10-Q/A filed on December 14, 2017.

Based on representations by FibroGen, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.17 to Form S-1 filed October 1, 2014 through October 20, 2020 Exhibit 10.18 to Form S-1 filed October 1, 2014 through October 20, 2020 Exhibit 10.16 to Form 10-Q/A filed December 14, 2017 through October 20, 2020

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary